Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ITIL-306

Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells, directed at folate receptor alpha (FOLR1) · developed by Instil Bio

Phase 1 Most advanced trial (none active)

TIL Developer

1 Registered trials

What is ITIL-306?

ITIL-306 is an autologous tumor infiltrating lymphocyte (TIL) cell therapy engineered to express a co-stimulatory antigen receptor (CoStAR) targeting folate receptor alpha (FOLR1). The therapy binds FOLR1-expressing tumor cells and activates TILs through costimulatory signals, enhancing T-cell proliferation and anti-tumor immune response. It is studied in epithelial ovarian cancer, non-small cell lung cancer, and renal cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (Tumor-infiltrating lymphocytes)
Targets: folate receptor alpha (FOLR1) (antigen)
Mechanism: Kills target cells, directed at folate receptor alpha (FOLR1)
Pathways: T-cell proliferation, T-cell activation, tumor cell killing
Therapy area: Oncology
Developer: Instil Bio (TIL)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05397093	Phase 1	Epithelial Ovarian Cancer	Terminated	TIL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Epithelial Ovarian CancerNon-small Cell Lung CancerRenal Cell Carcinoma

Other drugs acting on FOLR1

ABBV-901 Phase 1 Opugotamig Olatansine Phase 2 Sofetabart Mipitecan Phase 3 Torvutatug Samrotecan Phase 1 ZW191 Phase 1

More from Instil Bio

ITIL-168 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the TIL page.

Follow TIL, the company behind ITIL-306

See TIL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TIL catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z